Suzano (SUZB3) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
8 Sep, 2026Financial performance and governance
Net revenue reached US$9.0 billion LTM 2Q26, with adjusted EBITDA of US$3.8 billion and a 42% margin.
Net debt stands at US$12.8 billion, with a net leverage ratio of 3.4x.
Board of Directors includes 44% independent members and 22% women, supported by multiple committees.
Listed on B3's Novo Mercado and NYSE ADR Level 2, reflecting robust governance.
Conservative financial policy with commodity hedging and diversified global funding sources.
Strategic roadmap and competitiveness
Focus on enhancing competitiveness, disciplined growth, and extracting value from prior capital allocations.
Competitiveness acceleration program targets cost reduction and operational efficiency across the value chain.
Unique forestry capability, disciplined execution, and strategic wood swap transactions drive structural advantages.
Ribas do Rio Pardo mill outperformed expectations, increasing production capacity without additional capex.
Cost reduction initiatives leverage AI and process optimization, targeting R$80M–R$115M in savings.
Market dynamics and growth
Global market pulp demand continues to grow, led by China and tissue segments.
BHKP (hardwood pulp) is gaining market share over BSKP (softwood pulp) across all segments.
New integrated capacity in Asia and LatAm is reshaping the competitive landscape, with ongoing wood cost pressures.
Vertical integration in Asia expected to grow, but oversupply risks persist, requiring closures and downtime to balance.
Eucafluff® expansion to add 340kt/year by Dec 2025, supporting innovation in specialty pulp.
Latest events from Suzano
- Global pulp leader with strong financials, ESG focus, and disciplined growth through innovation and partnerships.SUZB3
Conference presentation - Adjusted EBITDA up 3% sequentially; free cash flow surged to R$ 3.3 billion.SUZB3
Q2 2026 - Pulp sales and prices up YoY, but profit and EBITDA fell; major tissue deal to close mid-2026.SUZB3
Q1 2026 - Record sales, strong EBITDA, and major acquisition highlight robust 2025 performance.SUZB3
Q4 2025 - Adjusted EBITDA dropped 20% YoY to R$5.2bn as lower pulp prices offset efficiency gains.SUZB3
Q3 2025 - Strong sales growth, robust cash flow, and major strategic moves marked the quarter.SUZB3
Q2 2025 - Net revenue and EBITDA surged on higher sales and FX gains, with leverage and liquidity improving.SUZB3
Q3 2024 - EBITDA up 60% YoY to R$6.3B, but net loss of R$3.8B on FX and derivative impacts.SUZB3
Q2 2024 - Net income surged to R$6.3B in 1Q25, driven by strong sales, FX gains, and cost discipline.SUZB3
Q1 2025